Research & Studies
Share your love
Luxa Biotechnology announces clinical trial results for treatment of AMD | Ophthalmology Times
(Image credit: ©Alex_Traksel/AdobeStock) Luxa Biotechnology LLC announced results from its phase 1/2a clinical trial titled “Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes.”1 The results were published…
Conavi Medical submits Novasight Hybrid IVUS/OCT System to FDA for 510(k) clearance | Ophthalmology Times
(Image Credit: AdobeStock/gguy) Conavi Medical has submitted its Novasight Hybrid™ IVUS/OCT intravascular imaging system to the US Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. While optical coherence tomography (OCT) is traditionally used to monitor retinal diseases,…
OKYO Pharma details next clinical stage of urcosimod development | Ophthalmology Times
OKYO Pharma has announced its plans for the next stage of clinical development of urcosimod (formerly OK-101), its lead drug candidate to treat neuropathic corneal pain (NCP). NCP is a condition that causes severe pain and sensitivity of the eyes, face,…
Q&A: Anat Loewenstein recaps the 2025 EURETINA meeting | Ophthalmology Times
Photo of Anat Loewenstein at EURETINA 2025 The 25th EURETINA conference was a landmark event, attracting 11,000 participants from around the world. Anat Loewenstein, MD, the 2025 The president of EURETINA, highlighted the meeting’s comprehensive scientific program, featuring sessions on…
Justis P. Ehlers, MD, on the HELIOS trial for NPDR | Ophthalmology Times
Note: Captions are generated with the assistance of AI. Justis Ehlers, MD, spoke with Ophthalmology Times to share key findings from his recent presentation at the 2025 Retina Society meeting, which was held in Chicago, Illinois. Ehlers shared data from…
Care of newly diagnosed POAG impacted by patient wealth, area of residence | Ophthalmology Times
(Image credit: AdobeStock/masud) The results of a new cohort study found that newly diagnosed primary open-angle glaucoma (POAG) in patients who were in the lowest wealth quartile was “substantially” less likely to reach the recommended reduction and the patients “considerably”…
Optos and Toku to incorporate BioAge AI into existing retinal imaging devices | Ophthalmology Times
(Image credit: AdobeStock/hakule) Optos and Toku have reached an agreement to make Toku’s BioAge available to users of Optos Daytona, Monaco, MonacoPro, and California devices in the United States. The companies state that by incorporating the AI solution, BioAge, eye…
iVeena secures $2 million NEI SBIR grant to advance pediatric myopia therapy | Ophthalmology Times
iVeena Delivery Systems has been awarded a $2 million phase 2 Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH). The funding will help to advance development of novel topical eye…
Part 6: What if? Curing any eye disease with the snap of your finger | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Virtual Vision Health and VirtuaLens enter partnership to accelerate virtual reality in eyecare | Ophthalmology Times
(Image credit: AdobeStock/matrosovv) Virtual Vision Health and VirtuaLens have entered a strategic partnership to expand access to and accelerate adoption of VR screening and patient education tools. The Virtual Eye VR platform from Virtual Vision Health offers an untethered, all-in-one…